1. Home
  2. MYN vs PEPG Comparison

MYN vs PEPG Comparison

Compare MYN & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniYield New York Quality Fund Inc.

MYN

Blackrock MuniYield New York Quality Fund Inc.

HOLD

Current Price

$9.92

Market Cap

390.0M

Sector

Finance

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$7.26

Market Cap

317.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYN
PEPG
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.0M
317.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
MYN
PEPG
Price
$9.92
$7.26
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$10.80
AVG Volume (30 Days)
86.0K
625.0K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
4.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.47
$0.88
52 Week High
$10.62
$7.80

Technical Indicators

Market Signals
Indicator
MYN
PEPG
Relative Strength Index (RSI) 41.23 74.12
Support Level $9.89 $5.19
Resistance Level $10.01 $5.90
Average True Range (ATR) 0.07 0.47
MACD -0.01 0.14
Stochastic Oscillator 12.50 80.18

Price Performance

Historical Comparison
MYN
PEPG

About MYN Blackrock MuniYield New York Quality Fund Inc.

Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Share on Social Networks: